Last update 21 Nov 2024

Azintamide

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Azintamid, Azintamide (INN), Ora-Gallin purum

+ [4]

Target-

Mechanism-

Therapeutic Areas

Digestive System Disorders

Active Indication

Cholestasis

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure

Molecular FormulaC10H14ClN3OS

InChIKeySSLKKMZJCJBOML-UHFFFAOYSA-N

CAS Registry1830-32-6

100 Clinical Results associated with Azintamide

100 Translational Medicine associated with Azintamide

100 Patents (Medical) associated with Azintamide

Literatures (Medical) associated with Azintamide

01 Mar 2017·Journal of AOAC INTERNATIONALQ4 · AGRICULTURAL & FORESTRY SCIENCE

Chromatographic Study of Azintamide in Bulk Powder and in Pharmaceutical Formulation in the Presence of Its Degradation Form

Q4 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Hegazy, Maha A ; Abdel Fattah, Laila E ; Hassanain, Waleed A ; El-Fatatry, Hamed M

AbstractTwo specific, sensitive, and precise stability-indicating chromatographic methods were developed, optimized, and validated for the determination of Azintamide (AZ) in the presence of its degradation product. The first method was TLC combined with the densitometric determination of the separated bands. Separation was achieved using silica gel 60 F254 TLC plates and chloroform–acetone–glacial acetic acid (7.5 + 2.1 + 0.4, v/v/v) as the developing system. Good correlations were obtained between the integrated peak area of the studied drug and its corresponding concentrations in the linearity range. The second method used HPLC with UV diode-array detection, in which the proposed method was applied for the quantitative determination of AZ in the presence of its acidic degradation product and the quantitative determination of the acid-induced degradation product of AZ (AZ Deg) using pentoxifylline as the internal standard. The proposed components were separated on a reversed-phase C18 analytical column using acetonitrile–water (50 + 50, v/v). The flow rate was maintained at 0.55 mL/min and the detection wavelength was 260 nm. Linear regressions were obtained in the range of 1–30 and 0.3–16 μg/mL for AZ and AZ Deg, respectively. Different parameters affecting the suggested methods were optimized for maximum separation of the cited components. The suggested methods were validated in compliance with the International Conference on Harmonization guidelines and successfully applied for the determination of AZ in its pure powder form and in its pharmaceutical formulation. Both methods were also statistically compared with the reported method with no significant difference in performance observed.

01 May 2016·Journal of Clinical MicrobiologyQ2 · MEDICINE

Phylogenetic Analysis of Invasive Serotype 1 Pneumococcus in South Africa, 1989 to 2013

Q2 · MEDICINE

Article

Author: Everett, Dean B. ; Klugman, Keith P. ; Jolley, Keith A. ; Wolter, Nicole ; Wadula, Jeannette ; Tempia, Stefano ; de Gouveia, Linda ; Mbelle, Nontombi ; Cornick, Jennifer E. ; Breiman, Robert F. ; Bentley, Stephen D. ; von Gottberg, Anne ; du Plessis, Mignon ; Gladstone, Rebecca A. ; von Mollendorf, Claire ; Allam, Mushal ; McGee, Lesley

ABSTRACT Serotype 1 is an important cause of invasive pneumococcal disease in South Africa and has declined following the introduction of the 13-valent pneumococcal conjugate vaccine in 2011. We genetically characterized 912 invasive serotype 1 isolates from 1989 to 2013. Simpson's diversity index (D) and recombination ratios were calculated. Factors associated with sequence types (STs) were assessed. Clonal complex 217 represented 96% (872/912) of the sampled isolates. Following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), ST diversity increased in children <5 years (D, 0.39 to 0.63, P = 0.002) and individuals >14 years (D, 0.35 to 0.54, P < 0.001): ST-217 declined proportionately in children <5 years (153/203 [75%] versus 21/37 [57%], P = 0.027) and individuals >14 years (242/305 [79%] versus 96/148 [65%], P = 0.001), whereas ST-9067 increased (4/684 [0.6%] versus 24/228 [11%], P < 0.001). Three subclades were identified within ST-217: ST-217 C1 (353/382 [92%]), ST-217 C2 (15/382 [4%]), and ST-217 C3 (14/382 [4%]). ST-217 C2 , ST-217 C3 , and single-locus variant (SLV) ST-8314 (20/912 [2%]) were associated with nonsusceptibility to chloramphenicol, tetracycline, and co-trimoxazole. ST-8314 (20/912 [2%]) was also associated with increased nonsusceptibility to penicillin ( P < 0.001). ST-217 C3 and newly reported ST-9067 had higher recombination ratios than those of ST-217 C1 (4.344 versus 0.091, P < 0.001; and 0.086 versus 0.013, P < 0.001, respectively). Increases in genetic diversity were noted post-PCV13, and lineages associated with antimicrobial nonsusceptibility were identified.

01 Mar 2011·Zhonghua nei ke za zhi

[Combination therapy of azintamid and domperidone in functional dyspepsia: a randomised, double-blind, placebo-controlled trial].

Article

Author: Li, Qi ; Wang, Xiu-di ; Wang, Dong-mei ; Zhao, Li ; Wang, Zhao-gang ; Xu, Le

OBJECTIVETo study the efficacy and safety of combined therapy of compound azintamid and domperidone in functional dyspepsia.METHODSA randomised, double-blind, placebo-controlled trial. Two hundred and eight patients with functional dyspepsia were randomly grouped into group A (experimental group, 102 cases) and group B (control group, 106 cases). The patients in the group A were given 2 tablets of compound azintamid 3 times a day in addition to domperidone 10 mg 3 times per day for four weeks. The patients in the group B were only given domperidone 10 mg 3 times per day for 4 weeks. The therapeutic efficacy was evaluated by modified Severity of Dyspepsia Assessment (mSODA) and Global Patient Assessment (GPA).RESULTSSubscore in mSODA: the change of bloating/pain intensity score in group A is -12.35 ± 5.48 while group B is -10.52 ± 4.65 (P = 0.009), the change of non-bloating/pain symptoms score in group A is -5.75 ± 3.31 while group B is -4.86 ± 2.65 (P = 0.033), and the change of satisfaction score in group A is 7.09 ± 3.78 while group B is 5.62 ± 3.54 (P = 0.004). The response rate in group A is 89.2% which is significantly higher than 76.4% in group B (P = 0.015). Other symptoms for response assessment included loss of appetite, early satiety, fullness after meal, diarrhea. No severe side-effect was found in both groups.CONCLUSIONSCombined therapy of compound azintamid and domperidone may lead to bigger improvement in overall efficacy and health related quality of life in patients with functional dyspepsia than use of motility medicine alone. Potential mechanisms that may account for the efficacy of compound azintamide in functional dyspepsia include modulation of visceral sensitivity and/or gastrointestinal motility.

100 Deals associated with Azintamide

External Link

KEGG	Wiki	ATC	Drug Bank
D07485	-	A05A	DB13992

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cholestasis	CN	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis